Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT03321539 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Start date: October 30, 2017
Phase: Phase 3
Study type: Interventional

To see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating patients with N2-3 nasopharyngeal carcinoma(NPC).

NCT ID: NCT03306121 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Start date: November 13, 2017
Phase: Phase 3
Study type: Interventional

To see the effect of induction chemotherapy(TPF) followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy (PF) in treating patients with high risk nasopharyngeal carcinoma (NPC).

NCT ID: NCT03267498 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Start date: February 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

NCT ID: NCT03240835 Active, not recruiting - Malnutrition Clinical Trials

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients

Start date: September 12, 2017
Phase:
Study type: Observational

The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.

NCT ID: NCT03130270 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS); the relationship between EBV DNA copy number and survival after radiotherapy or radiochemotherapy; Quality of life score (QoL); evaluation of drug safety.

NCT ID: NCT03074513 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03047265 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: February 4, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase II Randomized Trial to Compare Paclitaxel combined with DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT ID: NCT02973386 Active, not recruiting - Clinical trials for Local Advanced High Risk Nasopharyngeal Carcinoma

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Start date: January 2017
Phase: Phase 3
Study type: Interventional

This is a randomized,controlled,prospective phase III clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis.Exploring an Individualized comprehensive treatment plan which is reasonable,effective,low toxicity and fitting with Modern radiotherapy techniques for Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis.

NCT ID: NCT02958111 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

CAN
Start date: January 2017
Phase: Phase 3
Study type: Interventional

This is an randomized, controlled, multicenter phase 3 clinical trial. The purpose of this study is to evaluate the efficacy and safety of single-agent capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC).

NCT ID: NCT02915432 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Start date: December 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and neck squamous cell carcinoma and to determine the recommended phase II dose (RP2D)